Raj Manchanda
Directeur Technique/Scientifique/R&D chez NEUMORA THERAPEUTICS, INC.
Profil
Raj Manchanda is currently the Chief Technical Operations Officer at Neumora Therapeutics, Inc. Prior to this, he was the Chief Development Officer at Anokion US, Inc. from 2019 to 2023 and at Frequency Therapeutics, Inc. from 2016 to 2018.
Dr. Manchanda holds a doctorate degree from Yale University.
Postes actifs de Raj Manchanda
| Sociétés | Poste | Début |
|---|---|---|
| NEUMORA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2023 |
Anciens postes connus de Raj Manchanda
| Sociétés | Poste | Fin |
|---|---|---|
| Anokion US, Inc. | Corporate Officer/Principal | 01/07/2023 |
| KORRO BIO, INC. | Corporate Officer/Principal | 01/10/2018 |
Formation de Raj Manchanda
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEUMORA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
| Anokion US, Inc. |
